Table 1. Comparison of study design, sample size, triggers and ART procedure in different studies.
Author	Study Design	Size			Trigger		ART Procedure
		Total Participants	Intervention Group	Reference Standard group	Intervention group	Reference Standard Group	ART Procedure
Schachter et al., 2008	Prospective RCT	221	105	106	Triptorelin 0.2 mg + hCG 5,000 IU	hCG 5,000 IU	IVF and IVF-ICSI
Lin et al., 2013	Retrospective Cohort	376 (378 cycles)	191	187	Triptorelin 0.2 mg + rhCG 250 μg	rhCG 250 μg	IVF and IVF-ICSI
Decleer et al., 2014	Prospective RCT	120	61	59	Triptorelin 0.2 mg + hCG 5,000 IU	hCG 5,000 IU	IVF-ICSI
Mahajan et al., 2016	Prospective RCT	76	38	38	Leuprolide 1 mg + hCG 5,000 IU	hCG 10,000 IU	IVF-ICSI
Seval et al., 2016	Retrospective Case Control	156	84	72	Leuprolide acetate 0.5 mg + rhCG 250 μg	rhCG 250 μg	IVF and IVF-ICSI
Alleyassin et al., 2018	Prospective RCT	126	63	63	Triptorelin 0.2 mg + hCG 5,000IU	hCG 10,000 IU	IVF-ICSI
Ali et al., 2020	Prospective RCT	160	80	80	Leuprolide 1 mg + rhCG 250μg	rhCG 250 μg	IVF-ICSI
Haas et al., 2020	Prospective RCT	155	77	78	Buserelin 0.5 mg + 10,000 IU hCG	hCG 10,000 IU + Placebo (normal saline)	IVF and IVF-ICSI